183 related articles for article (PubMed ID: 38551047)
1. Design of Nanodrug Delivery Systems for Tumor Bone Metastasis.
Zhai X; Peng S; Zhai C; Wang S; Xie M; Guo S; Bai J
Curr Pharm Des; 2024; 30(15):1136-1148. PubMed ID: 38551047
[TBL] [Abstract][Full Text] [Related]
2. Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease.
Vanderburgh JP; Kwakwa KA; Werfel TA; Merkel AR; Gupta MK; Johnson RW; Guelcher SA; Duvall CL; Rhoades JA
J Control Release; 2019 Oct; 311-312():257-272. PubMed ID: 31494183
[TBL] [Abstract][Full Text] [Related]
3. Bone-Targeted Drug Delivery Systems and Strategies for Treatment of Bone Metastasis.
Katsumi H; Yamashita S; Morishita M; Yamamoto A
Chem Pharm Bull (Tokyo); 2020; 68(7):560-566. PubMed ID: 32611993
[TBL] [Abstract][Full Text] [Related]
4. Research progress of bone-targeted drug delivery system on metastatic bone tumors.
Hu B; Zhang Y; Zhang G; Li Z; Jing Y; Yao J; Sun S
J Control Release; 2022 Oct; 350():377-388. PubMed ID: 36007681
[TBL] [Abstract][Full Text] [Related]
5. Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model.
Rudnick-Glick S; Corem-Salkmon E; Grinberg I; Margel S
J Nanobiotechnology; 2016 Dec; 14(1):80. PubMed ID: 27919267
[TBL] [Abstract][Full Text] [Related]
6. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
7. Nanocarrier-Based Therapeutics and Theranostics Drug Delivery Systems for Next Generation of Liver Cancer Nanodrug Modalities.
Ruman U; Fakurazi S; Masarudin MJ; Hussein MZ
Int J Nanomedicine; 2020; 15():1437-1456. PubMed ID: 32184597
[TBL] [Abstract][Full Text] [Related]
8. Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives.
Edis Z; Wang J; Waqas MK; Ijaz M; Ijaz M
Int J Nanomedicine; 2021; 16():1313-1330. PubMed ID: 33628022
[TBL] [Abstract][Full Text] [Related]
9. Biomacromolecular carriers based hydrophobic natural products for potential cancer therapy.
Pan W; Gu F; Yan X; Huang J; Liao H; Niu F
Int J Biol Macromol; 2024 Jun; 269(Pt 2):132274. PubMed ID: 38734357
[TBL] [Abstract][Full Text] [Related]
10. Potential of targeted drug delivery system for the treatment of bone metastasis.
Vinay R; KusumDevi V
Drug Deliv; 2016; 23(1):21-9. PubMed ID: 24839990
[TBL] [Abstract][Full Text] [Related]
11. Polymeric Nanocarriers for Drug Delivery in Osteosarcoma Treatment.
Gu X; Ding J; Zhang Z; Li Q; Zhuang X; Chen X
Curr Pharm Des; 2015; 21(36):5187-97. PubMed ID: 26412359
[TBL] [Abstract][Full Text] [Related]
12. Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy.
Zhang J; Tang H; Liu Z; Chen B
Int J Nanomedicine; 2017; 12():8483-8493. PubMed ID: 29238188
[TBL] [Abstract][Full Text] [Related]
13. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain.
Gdowski AS; Ranjan A; Sarker MR; Vishwanatha JK
Nanomedicine (Lond); 2017 Sep; 12(17):2083-2095. PubMed ID: 28805551
[TBL] [Abstract][Full Text] [Related]
14. Bone-Targeted Nanoplatform Combining Zoledronate and Photothermal Therapy To Treat Breast Cancer Bone Metastasis.
Sun W; Ge K; Jin Y; Han Y; Zhang H; Zhou G; Yang X; Liu D; Liu H; Liang XJ; Zhang J
ACS Nano; 2019 Jul; 13(7):7556-7567. PubMed ID: 31259530
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of Cancer Chemotherapeutic Efficacy via Bone-Targeted Drug Delivery Carrier in Bone Metastases.
Xue X; Yu J; Lu F; Jiang H; Wang X
Drug Des Devel Ther; 2021; 15():4455-4468. PubMed ID: 34737552
[TBL] [Abstract][Full Text] [Related]
16. Agents targeting prostate cancer bone metastasis.
Mohammad KS; Fournier PG; Guise TA; Chirgwin JM
Anticancer Agents Med Chem; 2009 Dec; 9(10):1079-88. PubMed ID: 19719455
[TBL] [Abstract][Full Text] [Related]
17. Endogenous pH-responsive nanoparticles with programmable size changes for targeted tumor therapy and imaging applications.
Wu W; Luo L; Wang Y; Wu Q; Dai HB; Li JS; Durkan C; Wang N; Wang GX
Theranostics; 2018; 8(11):3038-3058. PubMed ID: 29896301
[TBL] [Abstract][Full Text] [Related]
18. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites.
Attia MF; Anton N; Wallyn J; Omran Z; Vandamme TF
J Pharm Pharmacol; 2019 Aug; 71(8):1185-1198. PubMed ID: 31049986
[TBL] [Abstract][Full Text] [Related]
19. Injectable Drug-Loaded Nanocarriers for Lung Cancer Treatments.
Yu HP; Aljuffali IA; Fang JY
Curr Pharm Des; 2017; 23(3):481-494. PubMed ID: 28292243
[TBL] [Abstract][Full Text] [Related]
20. The optimized drug delivery systems of treating cancer bone metastatic osteolysis with nanomaterials.
Cheng X; Wei J; Ge Q; Xing D; Zhou X; Qian Y; Jiang G
Drug Deliv; 2021 Dec; 28(1):37-53. PubMed ID: 33336610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
